| Ticker: GGEN | 4001 Lexington Avenue North | |
| Exchange: NASDAQ-National Market | Arden Hills, Minnesota 55126 | |
| Industry: Manufacturing | (612) 481-2105 |
| Type of Shares: | Common Shares | Filing Date: | 2/6/96 | |
| U.S. Shares: | 2,000,000 | Offer Date: | 3/27/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,000,000 | Offer Price: | $10.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.70 | |
| Offering Amount: | $24,000,000 | Selling: | $0.40 | |
| Expenses: | $650,000 | Reallowance: | $0.10 | |
| Shares Out After: | 7,121,141 |
| Manager | Tier | Phone |
| Montgomery Securities | Lead Manager | 4156272220 |
| A.G. Edwards & Sons, Inc. | Co-manager | (314) 289-3000 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $0.15 | Assets: | $0.82 | ||
| Net Income: | -$5.47 | Liabilities: | $10.52 | ||
| EPS: | -$2.69 | Equity: | -$9.70 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is developing oral therapeutics to treat and prevent a broad range of human gastrointestinal diseases. Using its proprietary processes, the company has produced polyclonal antibodies that target specific pathogens infecting the human GI tract, including bacteria and their toxins, parasites, fungi and viruses. These polyclonal antibodies are derived from bovine colostrum, the milk collected in the first few milkings of a dairy cow after its calf is born, and when administered orally to humans provide passive immunity within the GI tract. The company believes that its products in development could offer an attractive therapeutic alternative to tractional antibodies at a time when concern about increasing antibiotic resistance and emerging new pathogens is high. The company's lead product in development, Sporidin-G, is a polyclonal antibody product with specificity for Cryptosporidium parvum, which causes chronic life-threatening diarrhea in AIDS and other immunocompromised patients, such as patients undergoing chemotherapy for cancer. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for the funding of clinical trials, research and development activities, capital expenditures and lease expenses related to equipment, leasehold improvements, repayment of debt and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.